Zobrazeno 1 - 10
of 216
pro vyhledávání: ''
Autor:
Lei Bi, Fuqiong Zhou, Peng Meng, Bo Tang, Yidan Ren, Yunshan Wang, Yu-Cui Jiang, Weiping Chen, Qin Wang, Chuanxin Wang, Maoxiao Feng, Yuli Wang, Feiyan Chen, Qinlian Jiao, Lutao Du
Publikováno v:
Cancer Research. 81:2015-2028
Hepatocellular carcinoma (HCC) contains a subset of cancer stem cells (CSC) that cause tumor recurrence, metastasis, and chemical resistance. Histone deacetylase 11 (HDAC11) mediates diverse immune functions and metabolism, yet little is known about
Autor:
Emad A. Rakha, David M. Heery, Cíntia J. Monteiro, Kartikeya Bhardwaj, Nigel P. Mongan, Wilbert Zwart, Mansour Alsaleem, Steffi Oesterreich, Takaaki Fujii, Ian O. Ellis, Andrew R. Green, Stacey E. P. Joosten, Sasagu Kurozumi, Ken Shirabe, Simon J Johnston
Publikováno v:
Cancer Research. 81:PS6-11
Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancer and is typically ER+ and ERBB2 non-amplified. There is preclinical evidence that somatic ERBB2 mutation may provide an alternative and tractable mechanism for upregulation
Autor:
Dongsheng Tu, Timothy J. Price, Hagen F. Kennecke, Daniel L. Edelstein, Scott Kopetz, Frank Holtrup, Hannah Quinn, Anthony Dowers, Stanley R. Hamilton, Derek J. Jonker, John Zalcberg, Christos S Karapetis, Paul Waring, Jonathan M. Loree, Christopher J. O'Callaghan, Malcolm J. Moore
Publikováno v:
Clinical Cancer Research. 27:52-59
Purpose: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab
Autor:
Peter S. Hammerman, Jing Yuan, Lesley A. Mathews Griner, Peter Aspesi, Daniel J. McKay, Gwynn Pardee, Hui Qin Wang, Kelli-Ann Monaco, Ribo Guo, Kenneth Crawford, Stephania Widger, Darrin Stuart, Vesselina G. Cooke, Karen Bui, Felipa A. Mapa, Yuji Mishina, Mariela Jaskelioff, Jeffrey A. Engelman, Paul Fordjour, Emma Labrot, Giordano Caponigro, Stacy Higgins, Jessi Ambrose, John Fuller, Jinsheng Liang, John Green, Scott Delach
Publikováno v:
Clinical Cancer Research. 27:2061-2073
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental Design: LXH254 was profiled in biochemical, in vitro, and in vivo assay
Publikováno v:
Molecular Cancer Research. 18:835-846
Through the use of an unbiased, genome-scale CRISPR modifier screen, we identified NF1 suppression as a mechanism of resistance to EGFR inhibition in NRAS/KRAS/BRAFV600-wild-type colorectal cancer cells. Reduced NF1 expression permitted sustained sig
Autor:
Luisa Izzi, H. Wang, Victor Cohen, Christian Couture, Nicole Bouchard, Jason Agulnik, Valerie Higenell, Normand Blais, Lise Tremblay, Cyrla Hoffert, Caroline Rousseau, Mathilde Couetoux du Tertre, Gerald Batist, Razvan Diaconescu, Maud Marques, Suzan McNamara, Vincent Pelsser, Karen Gambaro, Alan Spatz, Archana Srivastava
Publikováno v:
Molecular Cancer Therapeutics. 18:1628-1636
Rearrangements in the anaplastic lymphoma kinase (ALK) gene are found in approximately 5% of non–small cell lung carcinoma (NSCLC). Here, we present a comprehensive genomic landscape of 11 patients with ALK+ NSCLC and investigate its relationship w
Publikováno v:
Cancer Research. 79:P5-11
Background: CDK4/6 inhibition combined with endocrine therapy is now a standard of care for advanced estrogen receptor (ER) positive breast cancer. Predictive genetic landscape and mechanisms of resistance to CDK4/6 inhibitors have not been described
Autor:
Rebecca J. Nagy, Paul A. VanderLaan, Bryan C. Ulrich, Stephen Wang, Magda Bahcall, Giulia Costanza Leonardi, Emily S. Chambers, Man Xu, Marzia Capelletti, Jihyun Choi, Richard B. Lanman, Mark M. Awad, Amanda J. Redig, Hideo Baba, Paul Kirschmeier, Yu Imamura, Elena Ivanova, Frederick H. Wilson, Lynette M. Sholl, Cloud P. Paweletz, Masayuki Watanabe, Sangeetha Palakurthi, Pasi A. Jänne, Mizuki Nishino, Daniel B. Costa
Publikováno v:
Clinical Cancer Research. 24:5963-5976
Purpose: MET inhibitors can be effective therapies in patients with MET exon 14 (METex14) mutant non–small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance. In this study, we characterize acquir
Autor:
Shinji Kohsaka, Masahito Kawazu, Kanju Saka, Shinya Kojima, Masaaki Nagano, Hirotaro Iwase, Hiroyuki Mano, Toshihide Ueno
Publikováno v:
Clinical Cancer Research. 24:5112-5122
Purpose: The advent of next-generation sequencing technologies has enabled the identification of several activating mutations of Erb-B2 receptor tyrosine kinase 2 (ERBB2) among various cancers. However, the significance of infrequent mutations has no
Autor:
Gregory Sliwoski, Jie He, Jens Meiler, Daniel J. Zabransky, Dan Ye, Ariella B. Hanker, CL Arteaga, Vincent A. Miller, Sarah Croessmann, James P. Koch, Lisa N. Kinch, Alshad S. Lalani, Richard E. Cutler, M Red Brewer, Jonathan H. Sheehan
Publikováno v:
Cancer Research. 79:PD3-05
ERBB2, the gene encoding HER2, is mutated in 2-4% of breast cancers. The HER2 tyrosine kinase inhibitor neratinib has shown clinical activity against breast cancers harboring HER2 activating mutations, suggesting these tumors depend on HER2 signaling